Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.730
+0.050 (2.98%)
Mar 6, 2026, 1:15 PM EST - Market open
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Inovio Pharmaceuticals stock have an average target of 9.00, with a low estimate of 3.00 and a high estimate of 18. The average target predicts an increase of 420.23% from the current stock price of 1.73.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2025.
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $5 → $6 | Buy | Reiterates | $5 → $6 | +246.82% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +73.41% | Aug 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $5 | Buy | Initiates | $5 | +189.02% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +189.02% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +651.45% | May 14, 2025 |
Financial Forecast
Revenue This Year
92.16K
from 217.76K
Decreased by -57.68%
Revenue Next Year
21.35M
from 92.16K
Increased by 23,060.18%
EPS This Year
-2.30
from -3.95
EPS Next Year
-1.46
from -2.30
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 105,000 | 43.6M | ||||
| Avg | 92,163 | 21.3M | ||||
| Low | 63,700 | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -51.8% | 47,180.6% | ||||
| Avg | -57.7% | 23,060.2% | ||||
| Low | -70.7% | 10,427.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.10 | -1.11 | ||||
| Avg | -2.30 | -1.46 | ||||
| Low | -2.36 | -1.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.